In our EuroBiotech roundup this week, Clal benefits from Pfizer-Medivation deal, Hansa posts Phase II data, NeuroVive jettisons COO and more.

In this week's EuroBiotech Report, FDA knocks Sanofi, Zealand off track, Gilead, Galapagos start Phase III program, Promethera plans IPO and more.

The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering.

In the same week that Medivation was bought out by Pfizer in a major $14 billion deal, its former vice president of clinical development Dr. Amy Peterson has…

Just two months after signing a CAR-T deal with Baylor, London-based Cell Medica has penned a new pact with University College London (UCL) to use its T-cell…

Promethera Biosciences is planning to IPO in April or May to raise €40 million for its pipeline of liver cell therapies.

Pfizer, $14 billion down after its biotech bonanza buyout of Medivation in cash this week, still has money in the pot to buy AstraZeneca’s antibiotics unit.

Clovis Oncology shares were up by about 30% in trading after market close--driven by expectations for its rucaparib to treat advanced ovarian cancer, which was…